News | January 24, 2025
Alivus Life Sciences delivers 12% revenue growth
EBITDA margins expand to 31.3%
EBITDA margins expand to 31.3%
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
With over 28 years of experience in the pharmaceutical industry, he is a seasoned Techno? Commercial professional and accomplished top management leader
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
Morepen Laboratories approves hiving off of medical devices business
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Subscribe To Our Newsletter & Stay Updated
